The pharmaceutical division of South Korea's Lotte Group is positioning itself for expansion as the global pharmaceutical industry shifts production away from Chinese manufacturers. Bloomberg posted on X, highlighting that this move is driven by increasing geopolitical tensions and uncertainties surrounding tariffs. Lotte Group aims to capitalize on these changes by enhancing its production capabilities and expanding its market presence. The company is strategically aligning itself to benefit from the evolving landscape in the pharmaceutical sector, which is influenced by the current geopolitical climate.